We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Cardiac Implant Infections Linked to Significant Morbidity

By HospiMedica International staff writers
Posted on 07 May 2012
A new study has found that patients with cardiac device infective endocarditis (CDIE) have a high rate of mortality and morbidity, and appear to benefit from early device removal.

Researchers at Duke University Medical Center (Duke; Durham, NC, USA), the University of New South Wales (Sydney, Australia), and 59 other institutions in 28 countries conducted a prospective cohort study using data from the International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS), conducted from June 2000 through August 2006. More...
The participants were hospitalized adults with definite endocarditis, as defined by modified Duke endocarditis criteria. The main outcome measures were in-hospital and one-year mortality, and the association between device removal during index hospitalization and outcome.

The results showed that CDIE was diagnosed in 177 of a total cohort of 2,760 patients with definite infective endocarditis; in-hospital and one-year mortality rates were 14.7% and 23.2%, respectively. The clinical profile of CDIE included advanced patient age (median age 71.2 years), causation by staphylococci (42.5% Staphylococcus aureus and 31.6% coagulase-negative staphylococci), and a high prevalence of health care associated infection. There was coexisting valve involvement in 66 (37.3%) of the patients, predominantly tricuspid valve infection, with associated higher mortality. A survival benefit at one year was found for device removal during the initial hospitalization (19.9%), compared to those who did not undergo device removal (38.2%). The study was published in the April 25, 2012, issue of the Journal of the American Medical Association (JAMA).

“The high rates of mortality emphasize the need for improved preventive measures, including optimal skin decontamination and appropriate antibiotic administration at the time of cardiac device insertion or manipulation, as well as careful attention to any invasive or intravascular procedures performed after device implantation,” concluded study coauthor Andrew Wang, MD, of Duke, and colleagues. “Given that numbers of cardiovascular implantable electronic devices placed are increasing rapidly, further studies on the prevention and treatment of device-related infective endocarditis are needed.”

Related Links:

Duke University Medical Center
University of New South Wales



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.